Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.evoqremedies.com | |
Market Cap | 18.85 Cr. | |
Enterprise Value(EV) | 28.43 Cr. | 2023-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.80 | Trailing Twelve Months Ending 2022-03 |
Price-Earning Ratio (PE) | 17.28 | Trailing Twelve Months Ending 2022-03 |
Industry PE | 48.68 | Trailing Twelve Months Ending 2022-03 |
Book Value / Share | 17.03 | Trailing Twelve Months Ending 2022-03 |
Price to Book Value | 0.81 | Calculated using Price: 13.86 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 1.36 Cr. | 13,600,000 Shares |
FaceValue | 10 |
1 Day |
|
+4.68% |
1 Week |
|
+6.62% |
1 Month |
|
+3.82% |
3 Month |
|
+2.67% |
6 Month |
|
-13.38% |
1 Year |
|
+0.43% |
2 Year |
|
|
5 Year |
|
|
10 Year |
|
4 years | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 49.78 | 1.34 | 186.89 | 9.13 | |
Return on Capital Employed (%) | 68.94 | 2.69 | 246.90 | 9.12 | |
Return on Assets (%) | 0.52 | 0.01 | 10.45 | 5.27 |
Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03* Rs. Cr. |
Shh. Funds | 0 | 0 | 1 | 23 | 25 | |
Non Curr. Liab. | 0 | |||||
Curr. Liab. | 2 | 6 | 7 | 10 | 10 | |
Minority Int. | ||||||
Equity & Liab. | 2 | 6 | 8 | 33 | 35 | |
Non Curr. Assets | 0 | |||||
Curr. Assets | 2 | 6 | 8 | 33 | 35 | |
Misc. Exp. not W/O | ||||||
Total Assets | 2 | 6 | 8 | 33 | 35 |
Particulars | 4 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Net Sales | 3 | 9 | 10 | 17 | |
Other Income | |||||
Total Income | 3 | 9 | 10 | 17 | |
Total Expenditure | -3 | -9 | -9 | -15 | |
PBIDT | 0 | 1 | 1 | ||
Interest | |||||
Depreciation | |||||
Taxation | 0 | 0 | |||
Exceptional Items | |||||
PAT | 0 | 1 | 1 | ||
Adjusted EPS | 10 | 1 |
Particulars | 4 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | 0 | 0 | -28 | |
Cash Fr. Inv. | |||||
Cash Fr. Finan. | 29 | ||||
Net Change | 0 | 0 | 0 | 2 | |
Cash & Cash Eqvt | 0 | 0 | 2 |
Thu, 25 May 2023
Submission Of Audited Financial Results For The Half Year And Financial Year Ended On 31St March 2023 Along With Auditor'S Report And Declaration In reference to captioned subject and pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we are hereby submitting the Audited Financial Results for the Half Year and Financial Year ended on 31st March 2023 along with Auditors Report and Declaration. |
Thu, 25 May 2023
Announcement under Regulation 30 (LODR)-Resignation of Director Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with Para A of Part A of Schedule III to the said Regulations we hereby inform you that Mr. Tarunkumar Patel (DIN: 09433349) has resigned as a Non-Executive Director of the Company with effect from 25th May 2023. Further the Company has received confirmation from Mr. Tarunkumar Patel (DIN: 09433349) that there is no other material reason for his resignation other than those which are provided in the resignation letter. |
Thu, 25 May 2023
Announcement under Regulation 30 (LODR)-Change in Directorate Pursuant to second proviso to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of the Company in their meeting held today i.e. 25th May 2023 at the Registered Office of the Company which commenced at 3:00 P.M. and concluded at 6:35 P.M. inter-alia has considered and approved:1. Audited Financial Results for the Half Year and Financial Year ended on 31st March 2023 along with Auditors Report and Declaration.2. Appointment of Mr. Dahyabhai Patel (DIN: 07061899) as a Managing Director of the Company w.e.f. 25th May 2023 subject to approval of the Shareholders in the General Meeting. 3. Resignation of Mr. Tarunkumar Patel (DIN: 09433349) as a Director of the Company w.e.f. 25th May 2023. |
Fri, 26 May 2023 |
|
|
|
|
|